# T2 Biosystems Inc. (TTOO)

Source: https://www.quantisnow.com/company/TTOO
Generated: 2026-11-09T01:17:18.033Z

- Ticker: TTOO
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Medical/Dental Instruments
- IPO year: 2014
- Website: t2biosystems.com

## About

T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance technology that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument for detecting pathogens associated with sepsis and Lyme disease, and other applications, as well as T2Candida Panel that identifies the species of Candida, a fungal pathogen known to cause sepsis directly from whole blood. In addition, it provides T2Bacteria Panel, a multiplex diagnostic panel that detects various bacterial pathogens associated with sepsis; T2SARS-CoV-2 Panel, a COVID-19 molecular diagnostic test; and T2Resistance Panel for the early and sensitive detection of carbapenemase-resistance markers. Further, it develops T2Cauris Panel, a multi-drug resistant pathogen; and T2Lyme Panel for the detection of various strains of Lyme disease-causing bacteria. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

## Latest TTOO news and filings

- 2025-07-10 20:51 UTC [Amendment: SEC Form 25-NSE/A filed by T2 Biosystems Inc.](https://www.quantisnow.com/insight/amendment-sec-form-25-nsea-filed-by-t2-biosystems-inc-6117082)
- 2025-07-10 20:07 UTC [SEC Form 25-NSE filed by T2 Biosystems Inc.](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-t2-biosystems-inc-6116822)
- 2025-04-04 21:47 UTC [SEC Form 8-K] [SEC Form 8-K filed by T2 Biosystems Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-t2-biosystems-inc-5978719)
- 2025-04-01 13:00 UTC [SEC Form NT 10-K filed by T2 Biosystems Inc.](https://www.quantisnow.com/insight/sec-form-nt-10-k-filed-by-t2-biosystems-inc-5968842)
- 2025-02-20 14:00 UTC [SEC Form 8-K] [SEC Form 8-K filed by T2 Biosystems Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-t2-biosystems-inc-5899409)
- 2025-02-14 21:30 UTC [SEC Form 8-K] [T2 Biosystems Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities](https://www.quantisnow.com/insight/t2-biosystems-inc-filed-sec-form-8-k-costs-associated-with-5891072)
- 2025-02-14 02:22 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by T2 Biosystems Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-t2-biosystems-inc-5888748)
- 2025-02-11 14:00 UTC [SEC Form 8-K] [SEC Form 8-K filed by T2 Biosystems Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-t2-biosystems-inc-5881306)
- 2025-01-21 22:19 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by T2 Biosystems Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-t2-biosystems-inc-5852468)
- 2025-01-17 14:23 UTC [SEC Form 8-K] [SEC Form 8-K filed by T2 Biosystems Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-t2-biosystems-inc-5849419)
- 2025-01-08 22:16 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by T2 Biosystems Inc.](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-t2-biosystems-inc-5840033)
- 2025-01-07 14:05 UTC [SEC Form 8-K] [T2 Biosystems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition](https://www.quantisnow.com/insight/t2-biosystems-inc-filed-sec-form-8-k-results-of-operations-5837091)
- 2025-01-07 14:00 UTC [T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results](https://www.quantisnow.com/insight/t2-biosystems-announces-preliminary-fourth-quarter-and-full-year-2024-5837022)
- 2025-01-03 21:30 UTC [SEC Form 8-K] [SEC Form 8-K filed by T2 Biosystems Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-t2-biosystems-inc-5831798)
- 2025-01-02 23:58 UTC [SEC Form 4] [SEC Form 4 filed by Director Liebman Seymour](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-liebman-seymour-5830030)
- 2025-01-02 23:55 UTC [SEC Form 4] [SEC Form 4 filed by Chief Commercial Officer Giffin Brett A.](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-commercial-officer-giffin-brett-5830026)
- 2025-01-02 23:46 UTC [SEC Form 4] [SEC Form 4 filed by Director Adams Laura Lee](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-adams-laura-lee-5830017)
- 2025-01-02 23:28 UTC [SEC Form 4] [SEC Form 4 filed by Director Cumming John W](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-cumming-john-w-5829982)
- 2025-01-02 23:20 UTC [SEC Form 4] [SEC Form 4 filed by General Counsel Gibbs Michael Terrence](https://www.quantisnow.com/insight/sec-form-4-filed-by-general-counsel-gibbs-michael-terrence-5829974)
- 2025-01-02 23:18 UTC [SEC Form 4] [SEC Form 4 filed by Director Saunders Ninfa](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-saunders-ninfa-5829973)
- 2025-01-02 23:16 UTC [SEC Form 4] [SEC Form 4 filed by Director Toft Robin](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-toft-robin-5829971)
- 2025-01-02 23:13 UTC [SEC Form 4] [SEC Form 4 filed by Officer Sperzel John J Iii](https://www.quantisnow.com/insight/sec-form-4-filed-by-officer-sperzel-john-j-iii-5829963)
- 2025-01-02 23:11 UTC [SEC Form 4] [SEC Form 4 filed by Director Elsbree David B](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-elsbree-david-b-5829962)
- 2025-01-02 23:07 UTC [SEC Form 4] [SEC Form 4 filed by CFO Sprague John M](https://www.quantisnow.com/insight/sec-form-4-filed-by-cfo-sprague-john-m-5829959)
- 2024-12-18 14:00 UTC [T2 Biosystems Announces Sale of Four T2Dx Instruments to Existing European Distributor](https://www.quantisnow.com/insight/t2-biosystems-announces-sale-of-four-t2dx-instruments-to-existing-5818250)
- 2024-12-17 14:00 UTC [T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally](https://www.quantisnow.com/insight/t2-biosystems-achieves-key-milestone-with-250000th-novel-sepsis-test-5816240)
- 2024-12-16 14:00 UTC [T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.](https://www.quantisnow.com/insight/t2-biosystems-announces-extension-of-multi-year-capital-equipment-supplier-agreement-5814271)
- 2024-12-13 14:00 UTC [SEC Form 8-K] [SEC Form 8-K filed by T2 Biosystems Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-t2-biosystems-inc-5812424)
- 2024-12-09 14:02 UTC [SEC Form 8-K] [T2 Biosystems Inc. filed SEC Form 8-K: Regulation FD Disclosure](https://www.quantisnow.com/insight/t2-biosystems-inc-filed-sec-form-8-k-regulation-fd-disclosure-5805018)
- 2024-12-09 14:00 UTC [T2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens](https://www.quantisnow.com/insight/t2-biosystems-announces-plans-to-license-its-proprietary-technology-to-5804984)
- 2024-11-20 21:30 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by T2 Biosystems Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-t2-biosystems-inc-5785185)
- 2024-11-15 14:54 UTC [SEC Form 8-K] [T2 Biosystems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition](https://www.quantisnow.com/insight/t2-biosystems-inc-filed-sec-form-8-k-results-of-operations-5778386)
- 2024-11-14 21:05 UTC [Earnings Date] [T2 Biosystems Announces Third Quarter 2024 Financial Results](https://www.quantisnow.com/insight/t2-biosystems-announces-third-quarter-2024-financial-results-5775450)
- 2024-11-14 20:49 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by T2 Biosystems Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-t2-biosystems-inc-5775203)
- 2024-11-14 20:38 UTC [SEC Schedule 13G] [SEC Form SC 13G filed by T2 Biosystems Inc.](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-by-t2-biosystems-inc-5775170)
- 2024-11-08 22:00 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by T2 Biosystems Inc.](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-t2-biosystems-inc-5763171)
- 2024-11-08 14:30 UTC [SEC Form 8-K] [SEC Form 8-K filed by T2 Biosystems Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-t2-biosystems-inc-5761290)
- 2024-11-07 02:02 UTC [SEC Schedule 13G] [SEC Form SC 13G filed by T2 Biosystems Inc.](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-by-t2-biosystems-inc-5756933)
- 2024-11-07 02:01 UTC [SEC Schedule 13G] [SEC Form SC 13G filed by T2 Biosystems Inc.](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-by-t2-biosystems-inc-5756932)
- 2024-11-05 13:00 UTC [Earnings Date] [T2 Biosystems to Report Third Quarter 2024 Financial Results and Business Updates on November 14, 2024](https://www.quantisnow.com/insight/t2-biosystems-to-report-third-quarter-2024-financial-results-and-5752385)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/TTOO
- Earnings history: https://www.quantisnow.com/earnings/TTOO
- Dividend history: https://www.quantisnow.com/dividends/TTOO
- Insider transactions: https://www.quantisnow.com/insiders/TTOO
- Options chain: https://www.quantisnow.com/options/TTOO
- SEC 8-K filings only: https://www.quantisnow.com/company/TTOO/8-k
- RSS and alerts for TTOO: https://www.quantisnow.com/docs/rss-feeds.md